Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
4-month open-label fingolimod safety study in relapsing multiple sclerosis
NL-OMON36707Phase 3Active, not recruiting
- Sponsor
- Novartis
- Start
- Oct 2010
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of fingolimod in multiple sclerosis (MS), sponsored by Novartis. Primary endpoints: Safety and tolerability, Bradyarrhythmia and AV conduction disturbances and 2 more. Started Oct 2010; status: active, not recruiting.
02
Drugs
fingolimod
03
Conditions
multiple sclerosis (MS)
Beyond the preview
Go deeper on NL-OMON36707.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON36707.